-
公开(公告)号：WO2013130669A8
公开(公告)日：2014-03-27
申请号：PCT/US2013028097
申请日：2013-02-27
Applicant: VERTEX PHARMA
Inventor： DOKOU ELENI , JAMZAD SHAHLA , CAESAR JOHN P JR , FAWAZ MAJED , DAS LAURA , GU CHONG-HUI , HURTER PATRICIA NELL , ISRANI MEGHNA JAI , JOHNSTON MEGHAN M , KNEZIC DRAGUTIN , KUZMISSION ANDREW G , WANG HONGREN
CPC classification number: A61K9/205 , A61K9/143 , A61K9/145 , A61K9/146 , A61K9/1611 , A61K9/1617 , A61K9/1623 , A61K9/1652 , A61K9/2009 , A61K9/2013 , A61K9/2018 , A61K9/2054 , A61K9/2072 , A61K9/2077 , A61K9/4808 , A61K9/485 , A61K9/4858 , A61K9/4866 , A61K31/47 , A61K47/02 , A61K47/12 , A61K47/20 , A61K47/26 , A61K47/38 , C07D215/56
Abstract: The present invention relates to pharmaceutical compositions containing a solid dispersion of N- [2,4-Bis( 1,1 -dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide including formulations of the solid dispersions into powders, granules and mini-tablets, methods for manufacturing and processing the powders, granules and mini-tablets, and methods for treating cystic fibrosis employing the pharmaceutical composition.
Abstract translation: 本发明涉及含有N- [2,4-双（1,1-二甲基乙基）-5-羟基苯基] -1,4-二氢-4-氧代喹啉-3-甲酰胺的固体分散体的药物组合物，其包括 粉末，颗粒和微型片剂的固体分散体，粉末的制造和加工方法，颗粒剂和迷你片剂，以及使用该药物组合物治疗囊性纤维化的方法。
-
2.发明公开CO-CRYSTALS OF MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR 审中-公开COSTRISTALLE VON MODULATOREN DES TRANSMEMBRANKONDUKTANZREGULATORS BEI ZYSTISCHER FIBROSE
公开(公告)号：EP3204358A4
公开(公告)日：2017-08-16
申请号：EP15849070
申请日：2015-10-07
Applicant: VERTEX PHARMA
Inventor： STROHMEIER MARK , CAESAR JR JOHN P , CONNELLY PATRICK RAYMOND , FAWAZ MAJED , LUSS-LUSIS EDUARD , MCCLAIN BRIAN R , MEDEK ALES , MIAO HAI , NTI-ADDAE KWAME WIREDU , YIN PING , ZHANG YUEGANG
IPC: C07D215/56 , A61K31/4704 , A61P11/00
CPC classification number: C07D215/56 , A61K31/225 , A61K31/47 , A61K45/06 , C07B2200/13 , C07C69/18 , C07C69/30 , C07C69/34 , C07C69/58 , C07C69/587
Abstract: The present disclosure relates to co-crystals comprising N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide (Compound 1) and a co-former and methods for their preparation. The present disclosure further relates to pharmaceutical compositions comprising the co-crystal forms, as well as methods of treatment therewith and kits.
Abstract translation: 本发明涉及包含N- [2,4-双（1,1-二甲基乙基）-5-羟基苯基] -1,4-二氢-4-氧代喹啉-3-甲酰胺（化合物1）和共晶 及其制备方法。 本公开还涉及包含共晶形式的药物组合物，以及用其治疗的方法和试剂盒。
-
公开(公告)号：MX389751B
公开(公告)日：2025-03-20
申请号：MX2018014873
申请日：2014-08-26
Applicant: VERTEX PHARMA
Inventor： KUZMISSION ANDREW G , GU CHONG-HUI , KNEZIC DRAGUTIN , DOKOU ELENI , WANG HONGREN , P CAESAR JR JOHN , DAS LAURA , FAWAZ MAJED , JOHNSTON MEGHAN M , ISRANI MEGHNA JAI , HURTER PATRICIA NELL , JAMZAD SHAHLA
Abstract: La presente invención se refiere a composiciones farmacéuticas que contienen una dispersión sólida de N-[2,4-Bis(1,1-dimetilletil)-5-hidroxifenil]-1,4-dihidro-4-oxoquinolin-3-carboxamida incluyendo formulaciones de dispersiones sólidas en polvos, gránulos y minicomprimidos, métodos para fabricar y procesar los polvos, gránulos y minicomprimidos, y métodos para tratar fibrosis quística empleando la composición farmacéutica.
-
公开(公告)号：AU2015330923A1
公开(公告)日：2017-05-25
申请号：AU2015330923
申请日：2015-10-07
Applicant: VERTEX PHARMA
Inventor： STROHMEIER MARK , CAESAR JR JOHN P , CONNELLY PATRICK RAYMOND , FAWAZ MAJED , LUSS-LUSIS EDUARD , MCCLAIN BRIAN R , MEDEK ALES , MIAO HAI , NTI-ADDAE KWAME WIREDU , YIN PING , ZHANG YUEGANG
IPC: C07D215/56
Abstract: The present disclosure relates to co-crystals comprising N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide (Compound 1) and a co-former and methods for their preparation. The present disclosure further relates to pharmaceutical compositions comprising the co-crystal forms, as well as methods of treatment therewith and kits.
-
公开(公告)号：HK1205690A1
公开(公告)日：2015-12-24
申请号：HK15106314
申请日：2015-07-02
Applicant: VERTEX PHARMA
Inventor： DOKOU ELENI , JAMZAD SHAHLA , CAESAR JOHN P JR , FAWAZ MAJED , DAS LAURA , GU CHONG-HUI , HURTER PATRICIA NELL , ISRANI MEGHNA JAI , JOHNSTON MEGHAN M , KNEZIC DRAGUTIN , KUZMISSION ANDREW G , WANG HONGREN
IPC: A61K20060101
Abstract: The present invention relates to pharmaceutical compositions containing a solid dispersion of N-[2,4-Bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide including formulations of the solid dispersions into powders, granules and mini-tablets, methods for manufacturing and processing the powders, granules and mini-tablets, and methods for treating cystic fibrosis employing the pharmaceutical composition.
-
Patent Agency Ranking
公开(公告)号：AU2013226076A2
公开(公告)日：2014-09-25
申请号：AU2013226076
申请日：2013-02-27
Applicant: VERTEX PHARMA
Inventor： DOKOU ELENI , JAMZAD SHAHLA , CAESAR JR JOHN P , FAWAZ MAJED , DAS LAURA , GU CHONG-HUI , HURTER PATRICIA NELL , ISRANI MEGHNA JAI , JOHNSTON MEGHAN M , KNEZIC DRAGUTIN , KUZMISSION ANDREW G , WANG HONGREN
Abstract: The present invention relates to pharmaceutical compositions containing a solid dispersion of N- [2,4-B is( 1, 1 -dimethy lethyl)-5 -hydroxypheny 1] - 1,4-dihydro-4-oxoquinoline-3 - carboxamide including formulations of the solid dispersions into powders, granules and mini- tablets, methods for manufacturing and processing the powders, granules and mini-tablets, and methods for treating cystic fibrosis employing the pharmaceutical composition.
-
公开(公告)号：CA2865519C
公开(公告)日：2018-01-02
申请号：CA2865519
申请日：2013-02-27
Applicant: VERTEX PHARMA
Inventor： DOKOU ELENI , JAMZAD SHAHLA , CAESAR JOHN P JR , FAWAZ MAJED , DAS LAURA , GU CHONG-HUI , HURTER PATRICIA NELL , ISRANI MEGHNA JAI , JOHNSTON MEGHAN M , KNEZIC DRAGUTIN , KUZMISSION ANDREW G , WANG HONGREN
Abstract: The present invention relates to pharmaceutical compositions containing a solid dispersion of N- [2,4-B is( 1, 1 -dimethy lethyl)-5 -hydroxypheny 1] - 1,4-dihydro-4-oxoquinoline-3 - carboxamide including formulations of the solid dispersions into powders, granules and mini- tablets, methods for manufacturing and processing the powders, granules and mini-tablets, and methods for treating cystic fibrosis employing the pharmaceutical composition.
-
公开(公告)号：AU2013226076A1
公开(公告)日：2014-09-18
申请号：AU2013226076
申请日：2013-02-27
Applicant: VERTEX PHARMA
Inventor： DOKOU ELENI , JAMZAD SHAHLA , CAESAR JR JOHN P , FAWAZ MAJED , DAS LAURA , GU CHONG-HUI , HURTER PATRICIA NELL , ISRANI MEGHNA JAI , JOHNSTON MEGHAN M , KNEZIC DRAGUTIN , KUZMISSION ANDREW G , WANG HONGREN
Abstract: The present invention relates to pharmaceutical compositions containing a solid dispersion of N- [2,4-B is( 1, 1 -dimethy lethyl)-5 -hydroxypheny 1] - 1,4-dihydro-4-oxoquinoline-3 - carboxamide including formulations of the solid dispersions into powders, granules and mini- tablets, methods for manufacturing and processing the powders, granules and mini-tablets, and methods for treating cystic fibrosis employing the pharmaceutical composition.
-
公开(公告)号：CA2865519A1
公开(公告)日：2013-09-06
申请号：CA2865519
申请日：2013-02-27
Applicant: VERTEX PHARMA
Inventor： DOKOU ELENI , JAMZAD SHAHLA , CAESAR JOHN P JR , FAWAZ MAJED , DAS LAURA , GU CHONG-HUI , HURTER PATRICIA NELL , ISRANI MEGHNA JAI , JOHNSTON MEGHAN M , KNEZIC DRAGUTIN , KUZMISSION ANDREW G , WANG HONGREN
Abstract: The present invention relates to pharmaceutical compositions containing a solid dispersion of N- [2,4-B is( 1, 1 -dimethy lethyl)-5 -hydroxypheny 1] - 1,4-dihydro-4-oxoquinoline-3 - carboxamide including formulations of the solid dispersions into powders, granules and mini- tablets, methods for manufacturing and processing the powders, granules and mini-tablets, and methods for treating cystic fibrosis employing the pharmaceutical composition.
-
10.发明专利
公开(公告)号：ES2702288T3
公开(公告)日：2019-02-28
申请号：ES15849070
申请日：2015-10-07
Applicant: VERTEX PHARMA
Inventor： STROHMEIER MARK , CAESAR JR , CONNELLY PATRICK RAYMOND , FAWAZ MAJED , LUSS-LUSIS EDUARD , MCCLAIN BRIAN R , MEDEK ALES , MIAO HAI , NTI-ADDAE KWAME WIREDU , YIN PING , ZHANG YUEGANG
IPC: C07D215/56 , A61K31/4704 , A61P11/00
Abstract: Una composición farmacéutica que comprende una cantidad terapéuticamente eficaz del Compuesto 1 y un portador o excipiente farmacéuticamente aceptable, en donde el Compuesto 1 se representa mediante la siguiente fórmula estructural:**Fórmula** y 20 además, en donde al menos el 30% del Compuesto 1 está presente como un co-cristal que comprende el Compuesto 1 y un triglicérido, en donde el triglicérido se elige de la siguiente fórmula estructural:**Fórmula** en donde R1, R2 y R3 son independientemente C1-29alifáticos.
-
-
-
-
-
-
-
-
-
Search Results
16
records
(took 0.02 seconds)
